Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice.
JSON
O' Donovan DH, Baker D, Ciotta G, Degorce SL, Demanze S, Dockerill M, Escudero-Ibarz L, Ireland L, Mao Y, Packer MJ, Robinson J, Scarfe G, Tang H, Valge-Archer V
Bioorg. Med. Chem. Lett. 96 (-) 129518 [2023-10-12; online 2023-10-12]
The NLRP3 inflammasome is a multiprotein complex that plays a critical role in activating the immune system in response to danger signals. Small molecule agonists of NLRP3 may offer clinical benefits in cancer immunology either as a monotherapy or in combination with checkpoint blockade, where it is hypothesised that their application can help to initiate an antitumor immune response. In this study, we report the discovery of quinazolines and 8-azaquinazolines as NLRP3 agonists and their chemical optimization to afford compounds with oral bioavailability in mice. We confirm that these compounds engage the NLRP3 inflammasome by verifying their dependence upon lipopolysaccharide (LPS) priming for cytokine release and the activation of Caspase-1. We further demonstrate pathway engagement through loss of activity in an NLRP3-knockout THP1 cell line. Based on their pharmacokinetic profile and biological activity, these compounds represent valuable tools to evaluate the therapeutic potential of NLRP3 activation in a pre-clinical setting.
PubMed 37838344
DOI 10.1016/j.bmcl.2023.129518
Crossref 10.1016/j.bmcl.2023.129518
pii: S0960-894X(23)00396-7